|
Welcome
|
|
11 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | press |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
| [ Print-friendly version ] |
| Aspirin Esomeprazole Chemoprevention Trial |
| ISRCTN | ISRCTN85156844 |
| ClinicalTrials.gov identifier | NCT00357682 |
| Public title | Aspirin Esomeprazole Chemoprevention Trial |
| Scientific title | A phase III, randomised, study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia (BM) |
| Acronym | AspECT |
| Serial number at source | N/A |
| Study hypothesis |
Study objectives amended as of 22/05/2007:
Primary objectives: 1. To assess whether intervention with aspirin result in a decreased mortality or conversion rate from Barrett’s metaplasia to adenocarcinoma or high grade dysplasia 2. To assess whether high dose PPI therapy decreases the mortality or conversion rate from Barrett’s Metaplasia to adenocarcinoma or high grade dysplasia Secondary objectives: 1. To assess whether there are there clinical and molecular risk factors than can be identified in BM for the development of BA 2. To assess the cost effectiveness of aspirin and/or PPI treatment in the prevention of BA. 3. To assess whether intervention with PPI and/or aspirin induces changes in the expression of molecular markers for BA 4. To assess whether molecular markers can be used to monitor disease and identify groups at high risk of conversion 5. To investigate new genes important in the progression of BA, as a unique tissue bank will be available with a complete endoscopic, histological, physiology and pharmaceutical history 6. To investigate host susceptibility genes and environmental (diet) versus gene interactions 7. To investigate how intervention with PPI and/or aspirin influences the timing and severity of acid reflux into the oesophagus and the change in concentrations of bile acids in the oesophageal aspirates Study hypothesis provided at time of registration: The aim of this trial is to see if high or low dose esomeprazole alone, or esomeprazole and aspirin together can help stop Barrett's oesophagus developing into oesophageal cancer. |
| Lay summary | |
| Ethics approval |
To be submitted as of 22/05/2007. The AspECT Trial Office will submit the study protocol and any amendments to a Main Research Ethics Committee in the UK and obtain favourable ethical opinion. The Investigator will submit this protocol, any supporting documentation and any amendments, to a Local Research Ethics Committee or similar body.
As of 04/02/2008 ethics approval information was added to this record as follows: Ethics approval received from East London and the City Research Ethics Committee 1 (ref: 04/Q0603/1). Amendment reviewed and approved on the 28th September 2007. |
| Study design | Phase III, multi-centre, randomised controlled trial. |
| Countries of recruitment | United Kingdom |
| Disease/condition/study domain | Barrett's oesophagus due to chronic reflux in the gullet |
| Participants - inclusion criteria |
Inclusion criteria amdended as of 22/05/2007:
1. Patients aged over 18 years 2. Patient with circumferential Barrett’s Metaplasia at least 1 cm long, and histologically proven intestinal metaplasia in at least one sample 3. Patient’s able to give written consent 4. Patient’s with World Health Organization (WHO) activity profile of 0 or 1 i.e. fully active and self-caring Inclusion criteria provided at time of registration: 1. Male between 40 - 75 years 2. At least 2 cm from the gastro-oesophageal junction of circumferential BM (histologically proven by intestinal metaplasia in at least one sample) 3. Able to give written consent 4. World Health Organization (WHO) activity profile of 0 i.e. fully active and self-caring |
| Participants - exclusion criteria |
Exclusion criteria amended as of 22/05/2007:
1. Patients with high grade dysplasia or carcinoma at enrolment; 2. Patients with medical conditions which would make completing endoscopies or the trial difficult to complete including: 2.1. Previous transient ischaemic attacks or cerebral vascular disease 2.2. Severe respiratory disease 2.3. Severe ischaemic heart disease or myocardial infarction in the previous 6 months 2.4. Inflammatory bowel disease 3. Patients who are on continuous aspirin or non-steroidal anti-inflammatories or Cox-2 inhibitors (more than 3 courses/year) 4. Patient’s with absolute contraindications to PPIs, aspirin or their excipients such as allergies, ulcers, renal impairment or use of oral anticoagulants 5. Pregnant or lactating women Exclusion criteria provided at time of registration: 1. High grade dysplasia or carcinoma at enrolment 2. Medical conditions which would make endoscopy or the trial difficult or failure to complete including transient ischaemic attacks or cerebral vascular disease, severe respiratory disease, severe ischaemic heart disease or recent myocardial infarction or inflammatory bowel disease 3. Patients who are on continuous aspirin or non-steroidal drugs (more than 3 courses/year) 4. Absolute contraindications (ulcers) or allergies to PPIs or aspirin such as renal impairment and oral anticoagulants |
| Anticipated start date | 01/03/2005 |
| Anticipated end date | 31/10/2018 |
| Status of trial | Ongoing |
| Patient information material | |
| Target number of participants | Target number of participants as of 22/05/2007: 5500 (5000 male, 500 female). Target number of participants provided at time of registration: 5000 |
| Interventions |
Please note that the doses of the drugs below were added as of 22/05/2007:
Arm A (Standard Therapy): 20 mg esomeprazole Arm B (Strong Acid Suppression): 80 mg esomeprazole Arm C (Standard Therapy + Aspirin): 20 mg esomeprazole + 300 mg aspirin Arm D (Strong Acid Suppression + Aspirin): 80 mg esomeprazole + 300 mg aspirin Please note that as of 22/05/2007 the anticipated start and end dates of this trial have been updated as follows: Anticipated start of recruitment date: 01/03/2005 Anticipated end of recruitment date: 31/03/2009 Anticipated end of follow-up date: 31/10/2018 The previous anticipated end date of this trial was 01/03/2007. |
| Primary outcome measure(s) |
Primary outcome measures added as of 22/05/2007:
The following will be assessed at 4 and 8 years and four yearly until the end of study: 1. Conversion to adenocarcinoma of the oesophagus 2. Conversion to high grade dysplasia 3. Death by all causes |
| Secondary outcome measure(s) |
Secondary outcome measures amended as of 20/06/2007:
The following will be assessed at 4 and 8 years and four yearly until the end of study: 1. Incidence of oesophagectomy 2. Stage of adenocarcinoma 3. Incidence of ablation therapy 4. Incidence of endoscopic mucosal resection 5. Quality of life, assessed by The Reflux Disease Questionnaire and the Euroqol-5 Dimensions (EQ-5D) Questionnaire 6. Molecular endpoints including genotype and mutational status Secondary outcome measures added as of 22/05/2007: 1. Oesophagectomy 2. Stage of adenocarcinoma 3. Ablation therapy 4. Endoscopic mucosal resection |
| Sources of funding | Cancer Research UK (CRUK) (UK) |
| Trial website | |
| Publications | |
| Contact name | Prof Janusz Jankowski |
| Address |
Oncology Clinical Trials Office (OCTO)
Department of Clinical Pharmacology Old Road Campus Research Building University of Oxford Old Road Campus off Roosevelt Drive Headington |
| City/town | Oxford |
| Zip/Postcode | OX3 7DQ |
| Country | United Kingdom |
| Tel | +44 (0)1865 617000 |
| Fax | +44 (0)1865 617010 |
| janusz.jankowski@clinpharm.ox.ac.uk | |
| Sponsor | The University of Oxford (UK) |
| Address |
Research Services
Wellington Square |
| City/town | Oxford |
| Zip/Postcode | OX1 2JD |
| Country | United Kingdom |
| research services@admin.ox.ac.uk | |
| Date applied | 17/01/2005 |
| Last edited | 04/02/2008 |
| Date ISRCTN assigned | 15/02/2005 |
|
|
|
|
|
| © 2012 ISRCTN unless otherwise stated. | |
|
|
|
|